Rapid PE Triage and Notification (PETN) vs Tempus ECG-AF

Rapid PE Triage and Notification (Tool A) emphasizes real-time notifications to clinicians via PACS, email, and mobile apps, along with mobile and desktop application access, streamlining acute care workflows. Its focus on immediate alerts and integrated communication for rapid triage offers a more direct and interactive user experience. Tempus ECG-AF (Tool B) provides a risk assessment that requires further clinical interpretation and integration into existing systems, making its direct user interaction less prominent.

Rapid PE Triage and Notification (Tool A) offers immediate, high-accuracy detection of suspected central pulmonary embolisms with 94% sensitivity and 93% specificity, directly impacting life-saving acute care decisions. Tempus ECG-AF (Tool B) provides valuable predictive risk assessment for future AF, enabling proactive management for a chronic condition. While both are clinically valuable, Tool A's impact on critical, time-sensitive diagnoses gives it a slight edge in immediate clinical impact.

Tempus ECG-AF (Tool B) provides clear CMS reimbursement information, including specific CPT codes (0764T and 0765T) and a Medicare rate of $128.90, effective January 1, 2025. This transparency regarding reimbursement significantly enhances its value proposition and financial viability for healthcare providers. Rapid PE Triage and Notification (Tool A) does not publicly disclose its pricing, making its economic value less transparent.

Rapid PE Triage and Notification (Tool A) is deployed in over 2,500 hospitals across more than 100 countries, highlighting its extensive global adoption and proven scalability. It offers flexible on-premise or cloud deployment options and emphasizes seamless integration with PACS, RIS, and EMR systems through its robust Rapid Enterprise Platform. Both tools are FDA-cleared, HIPAA compliant, and have BAAs, but Tool A demonstrates a more mature and broadly adopted enterprise infrastructure.

Tempus ECG-AF (Tool B) demonstrates a higher degree of innovation by being the first FDA-cleared AI algorithm in its category to predict the risk of new-onset atrial fibrillation within 12 months from standard 12-lead ECGs. This represents a novel application of AI for proactive risk identification from an inexpensive, widely available test. Rapid PE Triage and Notification (Tool A) innovates by accelerating acute diagnostic workflows through AI-powered image analysis and real-time notifications, which is highly valuable but perhaps less fundamentally novel in its data application.

RapidAI (Tool A) explicitly offers 24/7/365 customer support via email and phone, with dedicated technical service experts and a global presence. They also provide a content hub with expert guides and resources. Tempus AI (Tool B) offers support via email and local representatives but does not specify 24/7 availability or the same breadth of publicly documented support resources.